scholarly journals Entecavir-associated thrombocytopenia

2021 ◽  
Vol 35 ◽  
pp. 205873842110596
Author(s):  
Yi Yu ◽  
Hao Feng
Keyword(s):  
Platelet Count ◽  
Hepatitis B ◽  
Temporal Relationship ◽  
Antiviral Treatment ◽  
Nucleoside Analogues ◽  
Delayed Response ◽  
The Third ◽  
B Virus ◽  
Feasible Option ◽  
Daily Prednisone

Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*109/L to 3*109/L and was prone to gum bleeding and skin ecchymosis after she received ETV treatment for 88 days. As a treatment option, ETV was replaced by TDF immediately, frequent platelets transfusions and thrombopoietin were applied for several days, daily prednisone of 50 mg was concomitantly taken, and then platelet count improved after 10 days. She was diagnosed with entecavir-associated thrombocytopenia after analysis of the temporal relationship and exclusion of other causes of thrombocytopenia by blood and bone marrow examinations. Our case suggested that the platelet count should be monitored regularly in patients during ETV treatment, and it may be a feasible option to choose TDF to maintain antiviral treatment when entecavir-associated thrombocytopenia occurs.

scholarly journals Entecavir-Associated Thrombocytopenia: A Case Report and Review of the Pathophysiology, Diagnosis, and Treatment of a Rare but Reversible Cause of Thrombocytopenia

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Binoy Yohannan ◽  
Dai Chu N. Luu ◽  
Mark Feldman
Keyword(s):  
Platelet Count ◽  
Case Report ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
Temporal Relationship ◽  
Serum Antibody ◽  
Blood Parameters ◽  
Drug Induced ◽  
B Virus

Drug-associated thrombocytopenia is often unrecognized. We report a 76-year-old female with lymphoma who presented with easy bruising and oral bleeding. She had undergone screening for hepatitis B virus (HBV) prior to starting rituximab and was found to have hepatitis B core serum antibody (IgG anti-HBc). She was therefore treated with prophylactic entecavir 0.5 mg daily to prevent reactivation of HBV. Her initial platelet count was 136,000/mm3. Five days after starting entecavir, she presented with bruising and oral bleeding and was found to have a platelet count of 7,000/mm3. A coagulation profile and the rest of the blood parameters (RBC and WBC counts) were normal. Entecavir was stopped, and she was given 3 units of apheresed platelets followed by intravenous immunoglobulin (1 g/kg) for 5 consecutive days. Her platelet counts improved and normalized in one week. She was diagnosed with entecavir-induced thrombocytopenia based on the temporal relationship and after carefully excluding alternate causes of thrombocytopenia. This case highlights the importance of recognizing drug-induced thrombocytopenia (DITP) as a reversible cause of thrombocytopenia.

Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA

2015 ◽  
Vol 41 (08) ◽  
Author(s):  
C Klein ◽  
CT Bock ◽  
H Wedemeyer ◽  
T Wüstefeld ◽  
S Locarnini ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Virus Replication ◽  
Nucleoside Analogues ◽  
B Virus

scholarly journals ANALYSIS OF PLATELET COUNT ON FIBROSIS DEGREE IN CHRONIC HEPATITIS B PATIENTS

2018 ◽  
Vol 24 (2) ◽  
pp. 165
Author(s):  
Hairul Anwar ◽  
Mutmainnah Mutmainnah ◽  
Ibrahim Abdul Samad
Keyword(s):  
Chronic Hepatitis ◽  
Platelet Count ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Complete Blood Count ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Significant Difference ◽  
B Virus ◽  
Spearman Correlation Test

Chronic hepatitis B is an infectious liver disease caused by hepatitis B virus that persist for more than 6 months. Fibrosis is a result of fibrogenesis which is the formation of connective tissue (scarring) caused by liver tissue damage. Liver damage will affect the production of thrombopoetin causing disturbances in the balance between destruction and production of platelet resulting in decreased platelet counts. This study was a retrospective cross-sectional study by taking the data from medical records of chronic hepatitis B patients who were tested for complete blood count and fibroScan at the Dr.Wahidin Sudirohusodo Hospital Makassar from January 2014 to July 2016. The result showed a total of 323 chronic B hepatitis patients, 99 with severe fibrosis, 84 with moderate fibrosis and 140 with mild fibrosis. The Spearman correlation test showed a significant correlation between the platelet count and the degree of fibrosis (p <0.001) and showed a positive correlation between both of them with a very strong correlation (r = 0.802). The Kruskal-Wallis test showed a significant difference between platelet count and the degree of fibrosis (p<0.001). The conclusion is that a decreased platelet count is a sign of an increase in the degree of fibrosis in chronic hepatitis B patients. It is suggested to perform another study with larger samples based on the degree of fibrosis. 

scholarly journals Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review

2020 ◽  
Vol 28 ◽  
pp. 204020662092133 ◽  
Author(s):  
Mohamed A Abd El Aziz ◽  
Rodolfo Sacco ◽  
Antonio Facciorusso
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Literature Review ◽  
Nucleoside Analogues ◽  
B Virus ◽  
Effect Of Treatment ◽  
Related Mortality

Hepatitis B virus is mainly considered to cause hepatocellular carcinoma which is the fourth leading cause of cancer-related mortality worldwide. Treatment of Hepatitis B virus with nucleos(t)ide analogues can decrease the progression of the disease and subsequently decreases the incidence of hepatocellular carcinoma. In this review, we have discussed the different classes of nucleos(t)ide analogues used in the treatment of Hepatitis B virus and their relationship with the development of hepatocellular carcinoma. Furthermore, we discussed the effect of treatment of Hepatitis B virus with Nucleoside analogues (NAs) before, during and after surgery, chemoembolization, radiofrequency ablation, and chemotherapy for the treatment of hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document